Forced vital capacity (FVC), a spirometric measure of pulmonary function, reflects lung volume and is used to diagnose and monitor lung diseases. We performed genome-wide association study meta-analysis of FVC in 52,253 individuals from 26 studies and followed up the top associations in 32,917 additional individuals of European ancestry. We found six new regions associated at genome-wide significance (P < 5 × 10 −8 ) with FVC in or near EFEMP1, BMP6, MIR129-2-HSD17B12, PRDM11, WWOX and KCNJ2. Two loci previously associated with spirometric measures (GSTCD and PTCH1) were related to FVC. Newly implicated regions were followed up in samples from African-American, Korean, Chinese and Hispanic individuals. We detected transcripts for all six newly implicated genes in human lung tissue. The new loci may inform mechanisms involved in lung development and the pathogenesis of restrictive lung disease.
Pulmonary function is a heritable trait that can be reliably measured by spirometry and reflects the physiological state of the lungs and airways 1 . FVC, one of the most widely used measures of pulmonary function, approximates vital capacity. In conjunction with forced expiratory volume in 1 s (FEV 1 ), FVC is used to diagnose various respiratory diseases. A reduced ratio of FEV 1 to FVC (FEV 1 /FVC) indicates airflow obstruction when FEV 1 is reduced disproportionately relative to FVC. In contrast, a decreased FVC measure in the context of a normal to elevated FEV 1 /FVC ratio suggests a restrictive ventilatory defect. In clinical practice, FVC is often used as a surrogate measure of disease progression in patients with established restrictive lung disorders, such as idiopathic pulmonary fibrosis 2, 3 . Reduced FVC is a strong predictor of mortality in the general population, independent of FEV 1 and standard risk factors such as age and cigarette smoking [4] [5] [6] [7] [8] .
Measures of pulmonary function show familial aggregation, with evidence for genetic effects in twin and family studies 9, 10 . We previously reported associations between FEV 1 or FEV 1 /FVC and at least 27 genetic loci using large-scale meta-analyses of genome-wide association studies (GWAS) [11] [12] [13] [14] . Thus far, the genetic determinants of FVC have not been studied using GWAS methods. We conducted a comprehensive GWAS meta-analysis across 2 large consortia with cohorts of European ancestry-the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) and SpiroMeta-to identify common genetic variants associated with cross-sectional measures of FVC in 52,253 subjects of European descent. In each of 6 newly associated loci, we confirmed that the genes closest to the new variants were expressed in lung tissue and performed expression quantitative trait locus (eQTL) analyses in 762 whole-blood samples. We evaluated the new loci in 6,070 African Americans in the National Heart, Lung, and Blood Institute (NHLBI)-sponsored Candidate Gene Association Resource (CARe) Project, in a Chinese subset (n = 563) of the Multi-Ethnic Study of Atherosclerosis (MESA) Lung study, in a Hispanic subset (n = 849) of MESA Lung
A r t i c l e s cells (PBMCs) (Supplementary Note).
We assessed whether these SNPs were associated with gene expression in whole-blood cells (Supplementary Table 3 and Supplementary Note) and queried databases to determine whether these SNPs were located within known or predicted regulatory regions.
Stage 1 and 2 results
There were nine regions containing at least one SNP associated with FVC at P < 5 × 10 −7 in stage 1. Of these regions, two (GSTCD and PTCH1) had previously been reported in GWAS 12, 13 of spirometric traits (FEV 1 and FEV 1 /FVC) and were thus not evaluated further, leaving seven SNPs in seven loci for follow-up in stage 2.
Six loci had associations that reached genome-wide significance (P < 5 × 10 −8 ) for FVC in the meta-analysis of stages 1 and 2 ( Fig. 2 and Table 1 ). These loci were in or near the following genes: BMP6 (rs6923462, 6p24, intronic), EFEMP1 (rs1430193, 2p16.1, intronic), MIR129-2-HSD17B12 (rs4237643, 11p11.2, 54 kb upstream), PRDM11 (rs2863171, 11p11.2, 3 kb downstream), WWOX (rs1079572, 16q23.1, intronic) and KCNJ2 (rs6501431, 17q24.3, 800 kb downstream) ( Supplementary Fig. 2a-g ). Effect sizes were generally consistent across studies (Supplementary Figs. 3a-g and 4a-g ). Three of these regions (BMP6, EFEMP1 and PRDM11) also showed independent replication in stage 2 samples of European ancestry, with association P values below a Bonferroni-corrected threshold for seven tests (P < 7.14 × 10 −3 ) ( Table 1 ). The lowest P value (5.89 × 10 −13 ) for the meta-analysis effect estimate across stages 1 and 2 was found for SNP rs6923462 (intronic SNP in BMP6).
We evaluated the effect of the six new loci separately in eversmokers and in never-smokers, and effect sizes were consistent across smoking strata for all the variants (Supplementary Table 4) .
Multi-ancestry follow-up
To examine the portability of the identified loci to other ancestry groups, we evaluated the regions of our newly identified SNPs in African Americans, Hispanics, Chinese and Koreans. For three of these samples (African Americans, Hispanics and Chinese), we looked up the SNPs with minor allele frequency (MAF) of ≥0.05 within 200 kb in either direction of the sentinel SNP in individuals of European ancestry in the 1000 Genomes Project all-ancestries imputation panel 20 . For Koreans, we looked up SNPs with MAF of ≥0.05 within 200 kb of the sentinel SNP according to imputation to HapMap and the Korean panel. To determine the appropriate Bonferroni-corrected P-value threshold for declaring statistical significance in each ancestry group, we used the Nyholt method to calculate the effective number of independent variants, on the basis of pairwise linkage disequilibrium (LD) among the follow-up SNPs 21, 22 .
African Americans were participants of the Candidate CARe Project 23 . Baseline characteristics of the 6,070 African Americans in CARe are shown by cohort in Supplementary Table 2b . We performed regional meta-analyses of the 7,470 SNPs (MAF ≥ 0.05) within 200 kb of the sentinel SNPs in individuals of European ancestry using 1000 Combined sample size, stages 1 and 2 N = 85,170 
npg

A r t i c l e s
Genomes Project imputed data. Using the P-value threshold of 4.42 × 10 −5 (based on 1,132 independent tests), 78 SNPs in the region of EFEMP1 were significantly associated with FVC (lowest P = 1.63 × 10 −7 ) in African Americans. Our top hit at the EFEMP1 locus in samples from individuals of European ancestry (SNP rs1430193, T allele frequency = 0.37; Table 1 ) had a very different allele frequency in our replication African-American samples (T allele frequency = 0.71) and did not show statistically significant association (P = 0.13). As has recently been noted regarding extension of GWAS SNPs discovered in European populations to African-American populations 24 , the effect size was in the same direction but was attenuated in the African-American cohort (β = −15.79 ml in African Americans versus −23.75 ml in individuals of European ancestry). The top hit in African Americans for the EFEMP1 region (rs62164511, P = 1.63 × 10 −7 ) showed a decrease in FVC of 84.7 ml for each copy of the A allele (A allele frequency = 0.9) (Supplementary Table 5a ). LD (r 2 ) between the most significantly associated SNP in African Americans (rs62164511) and the most significantly associated SNP in individuals of European ancestry (rs1430193) was low (0.16), providing further evidence of allelic heterogeneity at this locus ( Supplementary Fig. 5a,b) . Baseline characteristics of the 563 Chinese subjects from MESA Lung are shown in Supplementary Table 2c . We performed regional analyses (±200 kb, MAF of ≥0.05) around the sentinel SNPs in individuals of European ancestry using 1000 Genomes Project imputation. The P-value threshold was set at 4.41 × 10 −5 (on the basis of 1,133 independent tests). None of the 7,436 investigated SNPs had associations that reached a statistical significance level below the predefined threshold.
Baseline characteristics of the 849 Hispanics from the MESA Lung study are shown in Supplementary Table 2d . We performed regional analyses of SNPs (MAF ≥ 0.05) within 200 kb of the sentinel SNPs in individuals of European ancestry using 1000 Genomes Project imputation. 
Gene set enrichment analysis
To identify plausible pathways associated with FVC, we broadened our focus beyond genome-wide significant variants by performing gene set enrichment analysis 25 on the entire set of GWAS variants that underwent meta-analysis. We queried approximately 2,000 gene sets, including canonical pathways and Gene Ontology (GO) functional categories. Using a false discovery rate (FDR) of <0.01, we identified 65 enriched pathways (Supplementary Table 6 ). Although the overrepresented gene sets encompassed diverse functions, many involved processes critical to organ development and tissue remodeling, including epithelial morphogenesis, cell proliferation, extracellular matrix development and remodeling, Notch signaling and cell adhesion. Other prominent pathways included acetylcholine binding and channel activity, smooth muscle contraction, glutamate receptor activity, immunity and transcriptional or DNA repair processes. Shown are FVC results for the leading SNPs, ordered by chromosome and position, for each independent locus associated (P < 5 × 10 −8 ) with FVC in a joint analysis of up to 85,170 individuals of European ancestry from the CHARGE-SpiroMeta GWAS (stage 1) and follow-up (stage 2). Two-sided P values are given for stage 1, stage 2 and the joint meta-analysis of both stages. P values corresponding to genome-wide significance (P < 5 × 10 −8 ) in the joint meta-analysis of all stages are indicated in bold. SNPs showing independent replication in stage 2 (P = 0.05/7 = 7.14 × 10 −3 ) are indicated with their stage 2 P value shown in bold. The sample sizes (N) shown are the effective sample sizes. The effective sample size is the product of sample size and imputation quality summed across studies. β values reflect effect size estimates with standard error (SE) in ml. Chr., chromosome.
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Gene expression
Expression profiles of genes from the six loci that were significantly associated in the meta-analysis of stages 1 and 2 (EFEMP1, BMP6, WWOX, KCNJ2, PRDM11 and HSD17B12) and the housekeeping gene GAPDH were examined in human lung tissue and primary cell samples using RT-PCR. We detected transcripts for all six newly implicated genes in lung tissue, HBECs and HASM cells. Transcripts for five of the six genes (excluding EFEMP1) were present in PBMCs ( Table 2 and Supplementary Figs. 6 and 7) .
Expression quantitative trait locus analysis in peripheral blood cells
We investigated whether the top SNPs or their proxies (r 2 ≥ 0.7) in the six newly implicated loci for FVC were associated with gene expression using eQTL data (Online Methods). Multiple SNPs in or near HSD17B12 showed significant cis-eQTL associations (P < 1 × 10 −4 ) in peripheral blood, with the strongest association represented by rs11037676 (a proxy of rs4237643, r 2 = 0.7) at a P value of 8.42 × 10 −81 (Supplementary Table 3 ). The sentinel SNP associated with FVC in this region (rs4237643) also exhibited a strong cis effect on HSD17B12 expression (P = 1.82 × 10 −35 ) (Supplementary Fig. 8 ). Furthermore, this SNP showed a significant cis-eQTL association in lymphoblastoid cell lines (P = 6.7 × 10 −11 ) 26 
eQTL analysis in lung tissue
To better assess the relevance of cis-eQTLs to lung biology, we queried a publically available database that included lung tissue (Genotype-Tissue Expression project, GTEx) 29 to further investigate the top SNPs and their proxies. Multiple SNPs that mapped to HSD17B12, including rs11037676 and the sentinel SNP rs4237643, were highly significant cis-eQTLs in human lung samples (P = 2.8 × 10 −26 and 7.2 × 10 −14 , respectively).
Fetal lung mRNA expression for genes associated with FVC
We investigated whether the genes we identified were differentially expressed relative to gestational age during two phases of normal human fetal lung development (Supplementary Table 7 ). There was strong evidence (P value controlling for FDR = 6.7 × 10 −6 ) for differential expression of PRDM11, suggesting that this gene might have an important role in utero in lung development. One probe for WWOX also showed correlation between lung expression and fetal age, although this correlation was not seen with other probes for the gene.
Putative regulatory variants
We queried the RegulomeDB 30 database to assess whether any of the newly identified FVC-associated SNPs (P < 1 × 10 −7 , n = 150 SNPs) were located in known or predicted regulatory elements, including regions of DNase I hypersensitivity, binding sites for transcription factors and promoter regions that have been biochemically characterized to regulate transcription. Five SNPs received high likelihood scores (based on the amount of supporting data) for mapping to regulatory regions and affecting gene expression; these included four variants upstream of HSD17B12 (rs9783304, rs2862996, rs10768966 and rs6485443) and one variant downstream of EFEMP1 (rs1430189). These variants showed evidence of eQTL, transcription factor binding and/or DNase I hypersensitivity peaks. 
DISCUSSION
The protein encoded by this gene is an integral membrane protein and inward-rectifier type potassium channel. The encoded protein, which has a greater tendency to allow potassium to flow into rather than out of a cell, probably participates in establishing action potential waveform and excitability of neuronal and muscle tissues.
A plus sign indicates that the gene is expressed in the cell type used, and a minus sign indicates that we did not detect gene expression at the mRNA level after 70 cycles of PCR. Amplification was followed in real time using gene-specific TaqMan probes, and final PCR products were visualized by gel electrophoresis. We used GAPDH (encoding glyceraldehyde-3-phosphate dehydrogenase) as a positive control for the cDNA, and this gene was expressed in all tissues. Chr., chromosome; HASM, human airway smooth muscle; HBECs, human bronchial epithelial cells; PBMCs, peripheral blood mononuclear cells.
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A r t i c l e s similar to the annual rate of decline in FVC ranging from 12 to 47 ml in the general population 31 . Expression analyses showed that all the top candidate genes at these loci were expressed in lung tissue and primary lung cells (HBECs and HASM cells). Two additional loci associated with FVC at genome-wide significance in the stage 1 analysis were previously associated with FEV 1 /FVC (PTCH1) or FEV 1 (GSTCD) [12] [13] [14] at genome-wide levels of significance in GWAS. The six new associations found in this analysis explain only a modest proportion of the additive polygenic variance in FVC (0.74%). Stage 2 effect size estimates were used to calculate the proportion of the variance explained by the six new loci, to avoid the effect of bias from winner's curse. When we take the other known loci for pulmonary function into account, the proportion of the additive polygenic variance explained is 1.78%, a finding that is comparable to those with many other complex traits 32 . Unexplained heritability has become a well-known phenomenon in genetic epidemiology 33 , and possible explanations include multiple effects of common variants, rare variant effects, gene-by-environment interactions, genegene interactions and epigenetic regulation-mechanisms that are not captured by existing GWAS platforms.
We and others previously identified 27 regions associated at genome-wide significance with FEV 1 , FEV 1 /FVC or both [11] [12] [13] [14] . Although FEV 1 and FVC are statistically correlated (r = 0.83 in the Rotterdam Study, adjusted for age, sex, height and height 2 ), these measures represent clinically different entities. FVC is used for the evaluation of restrictive ventilatory defects and is a predictor of mortality independent of FEV 1 , standard risk factors and even previous cardiovascular disease 5, 6 . In contrast, FVC and FEV 1 /FVC have a very low correlation (r = −0.08 in the Rotterdam Study, adjusted for age, sex, height and height 2 ). In this analysis, we were able to identify six new loci that are associated with FVC at genome-wide significance. Only two of the loci that were previously associated with FEV 1 or FEV 1 /FVC showed genome-wide significant association with FVC in our study (GSTCD and PTCH1) 12, 13 . The sentinel SNPs at each of the six newly associated loci showed consistent directions of effect on both FEV 1 Table 8 ). Among our FVC-associated SNPs, the smallest P value for FEV 1 (9.43 × 10 −7 ) was observed for rs1079572 (WWOX). An intragenic SNP (rs11654749) in the region between KCNJ2 and SOX9 was associated with FEV 1 at genome-wide significance in our previous meta-analysis of SNP and SNP-by-smoking effects 34 . To assess whether the variant identified in that analysis of FEV 1 (rs11654749) and the sentinel SNP from our current FVC analysis (rs6501431) are representative of the same signal, we fitted both variants together in the model using GCTA 35 software. The effect sizes of these SNPs increased slightly when they were fitted together, as expected given that the marginal correlation (r = 0.03) of their alleles was positive and the effects of these alleles on lung function were in opposite directions. Thus, these SNPs appear to represent independent signals.
and FVC (Supplementary
Two of the top loci for FVC (BMP6 and EFEMP1) have been associated with height in a previous GWAS 36 . The FVC-associated SNPs in or near these two genes show modest to weak correlation with the top SNPs from the GWAS of height 36 . For EFEMP1, the r 2 value between rs1430193 (for FVC) and rs3791675 (for height) was 0.45. For BMP6, the correlation between rs6923462 (for FVC) and two SNPs associated with height (rs3812163 and rs1219896) was low. For rs6923462 and rs3812163, the r 2 value was 0.01, and, for rs6923462 and rs1219896, the r 2 value was 0.02. Because we adjusted for height in our analysis, our findings are likely to be independent of height but might reflect genetic effects on body or organ size.
To assess whether our identified loci are associated with FVC across populations of different ancestry, we examined the associations of our main findings in African-American, Korean, Hispanic and Chinese subjects. Despite the limited size of these samples, 78 SNPs in the region of EFEMP1 had associations that reached the significance threshold of P < 4.42 × 10 −5 in African Americans. These results support the involvement of this locus in lung function in individuals of both European and African descent, although there was evidence for allelic heterogeneity between these populations. In the Korean data set, we found two SNPs in the region of our locus near KCNJ2 to be significantly associated with FVC. In the smaller samples of Chinese and Hispanic participants, none of the investigated SNPs were significantly associated with FVC, which may not be surprising given the greatly reduced power. In summary, despite smaller sample sizes, we were able to show significant evidence of association with FVC for the EFEMP1 locus in African Americans and for the locus downstream of KCNJ2 in Koreans.
A literature review identified candidate genes within the newly associated loci plausibly involved in lung growth and pathogenesis. For example, BMP6 is a member of the bone morphogenetic protein (BMP) family that constitutes a key canonical signaling pathway in the regulation of lung development, repair and response to injury 37 . BMP6 expression in bronchial epithelial cells has been reported to increase in experimental models of allergic airway inflammation 38 . EFEMP1 is part of the fibulin family of extracellular matrix glycoproteins and encodes fibulin-3. Targeted disruption of a member of this family, Efemp2 (also known as fibulin-4), has been shown to cause reduced elasticity and emphysematous morphology in the lungs of mice 39 . Expression of other members of the fibulin family (fibulin-1 and fibulin-5) seems to be influenced by TGFB1 (encoding transforming growth factor-β1), a gene previously linked to inflammation in individuals with chronic obstructive pulmonary disease (COPD) 40, 41 . WWOX might influence protein-induced apoptosis and behaves as a tumor suppressor gene in various types of neoplasms, including small-cell lung cancer 42 . Our analysis in fetal lung showed strong evidence of differential expression of PRDM11, suggesting that this gene has a role in development in utero. In addition, nuclear expression of PRDM11 has been shown in respiratory epithelial cells of the human bronchus in three subjects in the Human Protein Atlas 43 . Interestingly, our eQTL analysis showed highly significant cis effects of FVCassociated variants on HSD17B12 expression in multiple tissues, including lung. Furthermore, several of these SNPs were located within regulatory sites upstream of HSD17B12, suggesting that these variants might have a regulatory role in gene expression. Exploratory pathway analysis using all SNPs in the meta-analysis of FVC implicated multiple processes, including several involved in tissue development and remodeling. These findings suggest that distinct and identifiable biological pathways underlie the genetic basis of lung vital capacity in the general population.
There are some limitations to our analysis. With cross-sectional measures of FVC, we cannot determine whether the identified signals are due to influence on lung growth or age-related decline in lung function 44 . The primary analyses were not adjusted for pack-years (the duration of smoking in years multiplied by the number of cigarettes per day, divided by 20 cigarettes per pack) to avoid attrition in sample size, but, within the CHARGE cohorts, estimates from metaanalysis with and without adjustment for pack years were very similar (data not shown).
A key strength of our study is its considerable sample size of European-ancestry individuals. Our application of genomic control npg A r t i c l e s at the three stages is likely to be overly conservative because it has recently been shown that, in large meta-analyses, test statistics are expected to be elevated under polygenic inheritance, even when there is no population structure. Estimates of genomic inflation increase with sample size, as has been shown for other traits 14, 36, 45, 46 . Following the two-stage meta-analysis, we were able to test the associated SNPs and their regions for tissue-specific expression.
In conclusion, using a large-scale staged meta-analysis, we report six new loci associated with FVC and show that all are expressed in lung tissue and primary lung cells. Our findings point to previously unexplored pathways and mechanisms underlying lung function. Improvement of the understanding of the role that these genes have in normal lung development and pathogenesis could lead to the identification of novel therapeutic targets for lung diseases. In stage 2, we followed up SNPs showing association with FVC (P < 5 × 10 −7 ) and performed meta-analysis of β estimates and standard errors across stages 1 and 2. Stage 2 encompassed 32,917 subjects of European ancestry from 9 independent cohorts. All participants provided written informed consent. The study was approved by the institutional ethical committee of each study site and was conducted according to Declaration of Helsinki principles. Imputation. Imputation to the HapMap CEU panel (Utah residents of Northern and Western European ancestry) was conducted using either MACH 47 , IMPUTE 48 , Beagle 49, 50 or BIMBAM 51 with filters and quality control parameters as shown in Supplementary Table 9 . SNPs were excluded for a cohort if the imputation score, assessed using r2.hat (MACH), .info (IMPUTE) or OEvar (BIMBAM), was <0.3. In total, 2,762,059 SNPs were analyzed.
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Statistical analysis.
Individual studies performed a GWAS analysis using linear regression models with FVC (in ml) as the outcome, stratified by never-/ever-smoking. Adjustment factors were age, age 2 , sex and height (plus height 2 and weight for CHARGE and replication cohorts). If applicable, cohorts adjusted for center, cohort or principal components to adjust for population stratification. The follow-up studies used the same models. Effect estimates for each study were corrected using genomic control 19 separately within smoking strata. Study-specific λ estimates are shown in Supplementary Table 1. Meta-analysis of stage 1 data. Variants with imputation quality below 0.3 or MAF below 0.03 were excluded from each data set before the meta-analysis. Study-specific effect estimates and standard errors for ever-smokers and neversmokers were combined using METAL 52 with fixed-effects inverse varianceweighted meta-analysis, which takes directionality into account by aligning study results according to the same effect allele. Genomic control was applied to the resulting combined (ever-smokers and never-smokers) effect estimates for each study. These combined effect estimates for each study were then combined across studies, again using fixed-effects inverse variance-weighted metaanalysis with METAL, and genomic control was applied again to the final meta-analysis estimates. Manhattan plots, quantile-quantile plots, forest plots, gene annotation and additional statistics were produced using R version 2. Selection of SNPs for stage 2 and stage 2 meta-analysis. For every region containing at least one SNP showing evidence of association with FVC (P < 5 × 10 −7 ), the SNP with the smallest P value that also had N effective ≥ 80% (N effective is the product of sample size and imputation quality summed across studies) of the total stage 1 sample size was followed up in a second stage using in silico data from nine cohorts ( Fig. 1 and Supplementary Table 2a) . In total, seven SNPs were followed up. Results for variants with imputation quality (Supplementary Table 10 ) below 0.3 in a given study were excluded from the meta-analysis. Meta-analysis was performed on results across stage 2 studies using fixed-effects inverse variance-weighted meta-analysis with METAL 52 .
Regions were defined as independent if the leading SNP from one region was >500 kb from the leading SNP of any other region. We excluded two regions (GSTCD and PTCH1) from follow-up that were previously associated with FEV 1 or FEV 1 /FVC [12] [13] [14] .
Combined analysis of stage 1 and stage 2. We performed an inverse varianceweighted fixed-effects meta-analysis across stages 1 and 2 using METAL 52 and obtained two-sided P values for the resulting effect estimates.
Follow-up in other ancestry groups. To evaluate these loci across ancestry groups, we studied association with FVC in four samples of non-European ancestry. We used data from the NHLBI-sponsored CARe Project 23, 54 , which genotyped African Americans in ARIC, MESA, CHS, CARDIA, the Jackson Heart Study and the Cleveland Family Studies.
Analyses in CARe were carried out by cohort, and meta-analysis was performed using METAL 52 . Furthermore, we assessed the SNPs in Hispanic and Chinese participants from the MESA Lung study. Lastly, we investigated the loci in Korean participants from the Healthy Twin [15] [16] [17] and KARE3 (ref. 18 ) studies. For the Korean studies, analyses were carried out by cohort, and meta-analysis was performed. Individual studies performed GWAS analysis using linear regression models with FVC (in ml) as the outcome. Adjustment factors were age, age 2 , sex, height, height 2 , ever-/never-smoking and weight. We assessed the sentinel SNPs from the HapMap CEU reference panel that were available and SNPs from the regions of the identified loci on the basis of the location of the sentinel SNPs ±200 kb. Only SNPs with MAF ≥ 0.05 were included. The estimated number of independent tests per population sample and corresponding Bonferroni-corrected P values are shown in Supplementary Table 11 . The effective number of independent variants being tested in each replication population was estimated on the basis of linkage disequilibrium between SNPs using the technique of Li and Ji 22 , which is a modification of the technique originally proposed by Cheverud 55 and implemented by Nyholt 21 . This calculation was performed using matSp-D 21 on the basis of the linkage disequilibrium structures of the 1000 Genomes Project all-ancestries sample.
Gene set enrichment analysis. We applied an algorithm known as improved gene set enrichment analysis for GWAS (i-GSEA4GWAS) to place variants associated with FVC within curated pathways and functional categories 25 . SNPs from the stage 1 and 2 GWAS meta-analysis were mapped to genes if they were within 100 kb (upstream or downstream). For a given SNP, if multiple genes were located within this range, the closest gene was selected and assigned the association P value. Because multiple SNPs can map to the same gene, SNP label permutation was used to reduce biases caused by larger loci having disproportionately higher number of SNPs. Log-transformed association P values were used to rank order the resulting gene list (18, 454 genes) and to calculate gene set enrichment scores. Approximately 2,000 gene sets were used. These were limited to curated pathways derived from multiple resources such as KEGG, BioCarta, REACTOME and functional annotations extracted from the Gene Ontology database. A modified version of the GSEA procedure was performed, and P values were adjusted for multiple testing using FDR. Significant enrichment of gene sets was set at FDR < 0.01.
Gene expression analysis.
After the meta-analysis, we investigated the mRNA expression of the nearest gene for each of the new SNPs in: human lung tissue, HASM cells, HEBCs and PBMCs. Lung resection specimens were obtained from individuals diagnosed with solitary pulmonary tumors at Ghent University Hospital (Ghent, Belgium). Primary human bronchial epithelial cells (HBECs) and human airway smooth muscle cells (HASM cells) were prepared from lung resection specimens obtained from anonymous donors during surgery for lung cancer at the Leiden University Medical Center (LUMC, Leiden, the Netherlands). All assays were carried out at the Ghent University Hospital. PBMCs were isolated from whole blood using Ficoll gradients. Written informed consent was obtained from all subjects according to protocols approved by the local ethics committees. Total RNA was extracted from samples using the miRNeasy Mini kit (Qiagen), and cDNA was prepared from 1 µg of RNA template using the Transcriptor Universal cDNA Master kit npg
